Search Results

Trenchant Technologies Capital (CSE: AITT) (OTC: AITTF) (FSE: 5730) “Trenchant” or “the Company”), is pleased to announce that its portfolio company GNQ Insilico (“GNQ”) has demonstrated promising results in synthesizing digital twins of human patients, and simulating the effects of an infertility drug on these digital replicas using its proprietary AI-driven platform.

“In-silico Drug Discovery Market” in terms of revenue was estimated to be worth $10.9 Bn in 2023 and is poised to reach $40.3 Bn by 2031, growing at a CAGR of 18.05% from 2024 to 2031 according to a new report by InsightAce Analytic.

The CEO of Insilico Medicine, which recently became the first company to launch Phase II trials for a drug developed using generative AI, spoke with BioSpace about the rise of the technology.

Insilico’s AI platform has attracted interest from a growing number of biopharma companies. Meanwhile, several other firms highlight their own AI technologies.

The Menarini Group and Stemline Therapeutics, Inc. announced that they have entered into an exclusive licensing agreement granting Stemline the global rights to develop and commercialize a novel, small molecule KAT6A inhibitor designed using Insilico’s AI platform, as a potential treatment for hormone sensitive cancers and other oncology indications.

Exelixis, Inc. and Insilico Medicine (“Insilico”) today announced that the companies have entered into an exclusive license agreement granting Exelixis global rights to develop and commercialize ISM3091, a potentially best-in-class small molecule inhibitor of USP1, which has emerged as a synthetic lethal target in the context of BRCA-mutated tumors.

Insilico Medicine today announces that China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for ISM3312, an orally available 3CLpro inhibitor generated and designed with the support of Insilico’s proprietary generative chemistry platform Chemistry42 for the treatment of COVID-19.

Insilico Medicine (“Insilico”), a clinical-stage end-to-end generative artificial intelligence (AI)-driven drug discovery company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to INS018_055 for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

Pattern Computer®, Inc. announced at the Bio International Conference in San Diego that it is filing provisional patent applications with the United States Patent Office which covers 14 insilico discoveries in the form of potentially synergistic drug combinations for metastatic castrate resistant prostate cancer.